Pliant Therapeutics Inc. (PLRX)
PLRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1746473/000174647326000037/0001746473-26-000037-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PLRX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001746473 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$149.3M |
| Operating income | -$156.4M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $45.4M |
| Total assets | $225.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $26.6M cash; operating cash flow -$16.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 61,990,635 (2026-11-09); 61,449,385 a year earlier; 59,895,958 three years earlier. | Cover page 2026-11-09 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-03-30 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-25 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $164K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$24.4M | -$17.0M | $26.6M | $0 | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | Not filed | -$22.4M | -$12.8M | $24.9M | $0 | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2026 2026-03-31 | Not filed | -$20.0M | -$19.2M | $22.2M | $0 | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2025 2025-12-31 | Not filed | -$23.6M | -$17.8M | $45.4M | $0 | $0 | 10-K 2026-03-11 |
| Q3 2025 2025-09-30 | Not filed | -$26.3M | -$21.1M | $93.7M | $30.4M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$43.3M | -$40.6M | $86.8M | $30.4M | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$56.2M | -$48.9M | $91.9M | $30.3M | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | $0 | -$49.7M | -$47.7M | $71.2M | $30.2M | $0 | 10-K 2026-03-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-30 |
| Latest annual report | 10-K | 2026-03-11 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-22 |
Source: SEC EDGAR submissions feed, 440 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.0% |
| 1 month | -28.0% |
| 3 months | -35.5% |
| Year to date | -42.9% |
| 1 year | -59.5% |
| From 52-week high | -58.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IBO | Impact BioMedical Inc. | $4.91 | -4.47% | $42.4M |
| ELTX | Elicio Therapeutics Inc. | $1.48 | -1.33% | $41.9M |
| GANX | Gain Therapeutics Inc. | $0.9402 | -9.60% | $41.9M |
| ONCY | Oncolytics Biotech Inc. | $0.3399 | -8.14% | $44.6M |
| HYFT | MindWalk Holdings Corp. | $0.9378 | -8.95% | $44.6M |
| TLPH | Talphera Inc. | $0.8609 | -4.98% | $44.7M |
| NMAD | Nomad Power Solutions Inc. | $2.80 | +19.15% | $45.1M |
| MIST | Milestone Pharmaceuticals Inc. Common Shares | $0.3650 | -29.81% | $45.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier